SC
EDIT icon

Scholtz & Company’s Editas Medicine EDIT Stock Holding History

Scholtz & Company’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,105
Closed -$233K – 73
2021
Q2 		$233K Buy
+4,105
New +$152K 0.08% 66
2021
Q1 		– Sell
-5,955
Closed -$418K – 75
2020
Q4 		$418K Buy
+5,955
New +$245K 0.16% 60

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Scholtz & Company's EDIT Position: Q3 2021 in Review

Scholtz & Company sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 4,105 shares — an estimated $233K sold.

Scholtz & Company first reported a position in EDIT in Q4 2020 and held it in 2 quarters. The position peaked at $418K in Q4 2020. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

  • Scholtz & Company reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
  • Scholtz & Company sold 4,105 Editas Medicine shares in Q3 2021, an estimated $233K.
  • Scholtz & Company first reported a position in Editas Medicine in Q4 2020 and held it in 2 quarters.
  • Scholtz & Company's Editas Medicine position peaked at $418K in Q4 2020.
  • 318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Scholtz & Company's 13F filing for Q3 2021, filed 15 Nov 2021.